What is this notice about?
The Alaska Department of Health's Pharmacy and Therapeutics Committee will meet online and by phone on Friday, November 20, 2026 at 8:00 a.m. to review the Preferred Drug List, the list of medicines the state's Medicaid program prefers to cover. The public, health care professionals and drug companies can send written material ahead of time or ask to speak during the meeting.
Why was this notice issued?
The Division of Health Care Services is sponsoring a meeting of the Pharmacy and Therapeutics Committee to address the Preferred Drug List.
What action is being taken?
Holding a teleconference-only committee meeting to review drug classes on the Preferred Drug List, and accepting written submissions and spoken public comment related to the agenda items.
Who is involved: Pharmacy and Therapeutics Committee; Department of Health, Division of Health Care Services; Prime Therapeutics (webinar host); pharmaceutical manufacturers; health care professionals; members of the public
How can the public respond?
Respond by Wed, Nov 18, 2026 10 days from today.
“Public submissions should be received no later than November 18, 2026 to allow inclusion in the meeting. Pharmaceutical manufacturer Clinical Submissions accepted until November 6, 2026 at 4:00pm AK local time.”
Ways to respond
- Email doh.hcs.pharmacy.info@alaska.gov
- Mail 4601 Business Park Blvd, Bldg K, Anchorage, AK 99503
- Email (written comments) matthew.parrott@alaska.gov
- Online form (pharmaceutical manufacturers only) https://health.alaska.gov/dhcs/Documents/pdl/Documents/AK_Submission_Request_Form_for_Pharmaceutical_Manufacturers.pdf
- Testify at meeting Send a message through the webinar Chat function to the host during the meeting
What to include
Anyone sending material must include a conflict of interest form, found at https://health.alaska.gov/dhcs/Documents/pharmacy/forms/Alaska-Medicaid-Clinical-Coverage-Review-Request-Disclosure-Form.pdf. Drug manufacturers must use the Clinical Submission form. To speak at the meeting, send the host in the Chat: (1) your name and credentials, if any; (2) who you represent (company, self, organization, group); (3) the drug class you want to comment on; and (4) any conflict of interest disclosure, such as financial ties to the topic. Alaskan health care professionals not tied to industry may comment at the start of the meeting; industry representatives are called on during the matching drug class discussion and are limited to 3 minutes. Industry presentations must follow federal rules, and any misrepresentation will be reported to the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion. Speakers must disclose conflicts of interest before addressing the committee. The meeting is being recorded. Agendas are posted at https://health.alaska.gov/en/education/pdl-preferred-drug-list/.
Contact
Matthew Parrott
State of Alaska, Department of Health, Division of Health Care Services
matthew.parrott@alaska.gov
907.334.2425
4601 Business Park Blvd, Bldg K, Anchorage, AK 99503
Will there be public meetings?
-
Pharmacy and Therapeutics Committee meeting: Fri, Nov 20, 2026, 8:00 a.m. Alaska time
Teleconference and online webinar only (Microsoft Teams)
Register at https://events.teams.microsoft.com/event/5370d856-b685-44be-8dab-e68ce09ec3ad@34c95ba7-5ec6-4527-bc5e-b33b58104992 and you will receive a confirmation email with joining information. To join by phone, dial 1.844-730-9010 (Toll Free), Webinar ID: 474 976 582#
Key dates
- Nov 6, 2026: Deadline for pharmaceutical manufacturer Clinical Submissions (4:00pm AK local time)
- Nov 18, 2026: Deadline for public and health care professional written submissions to be received for inclusion in the meeting
- Nov 18, 2026: Deadline to request disability accommodations from Matthew Parrott at 907.334.2425 (2:00 p.m.)
- Nov 20, 2026: Pharmacy and Therapeutics Committee meeting at 8:00 a.m.
Original notice text
This summary was written by an AI model (Claude) from the official notice text. This is general information, not legal advice. Always confirm deadlines and instructions in the official notice. Legal disclaimer.